UCL seals license with Finnish biotech Cerebricon

Licensing

Cerebricon Ltd of Kuopio, Finland, has agreed an exclusive license with University College London (UCL) & UCL Business to breed and use the NK1R -/- mouse, which expresses all of the core features of Attention Deficit Hyperactivity Disorder (ADHD). The company will use this model in its drug discovery services business.

Antti Nurmi, Cerebricon’s Head of Central Nervous Systems Models and Development, stated “We are pleased to have made this agreement with UCL Business and particularly pleased to have the opportunity to commercialise this model. Cerebricon already has a broad range of behavioral tests for psychiatry and with the inclusion of this model we will apply additional modalities such as microdialysis and our in-house MRI technologies.

Abbie Watts, UCL Business said, “In partnership with Cerebricon we think that our model of ADHD will become the gold standard for assessing the efficacy of new ADHD drugs. We know that ADHD is a complex pathology but we think we have found the best validated and best in class model of the disease.”